STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing

Rhea-AI Summary
Gilead Sciences announces positive results from Phase 3 trial of Trodelvy in metastatic triple-negative breast cancer, boosting hopes for improved treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
News

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Rhea-AI Summary
Gilead Sciences, Inc. presents new data on Biktarvy for people with HIV and comorbid conditions at the 31st CROI. Studies evaluate efficacy and safety for HIV/HBV and HIV/TB coinfections. Positive results show potential benefits of Biktarvy in treating both conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
News

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Rhea-AI Summary
Gilead Sciences and Merck announce positive Phase 2 clinical study results for a potential long-acting oral combination treatment for people with HIV. The investigational combination of islatravir and lenacapavir maintained a high rate of viral suppression at 24 weeks, supporting its development as a once-weekly oral regimen. This novel treatment option aims to address adherence and stigma challenges faced by individuals with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
News

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Rhea-AI Summary
Gilead Sciences and Merus N.V. collaborate to develop novel trispecific antibodies targeting dual tumor-associated antigens. Merus to lead early-stage research with Gilead having the option to license resulting programs. The agreement includes upfront payments, equity investment, and potential milestone payments totaling up to $1.5 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
News

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Rhea-AI Summary
Gilead Sciences, Inc. (GILD) announces positive real-world data on Veklury (remdesivir) at CROI, showing reduced risk of long-COVID symptoms and mortality among hospitalized COVID-19 patients, including the immunocompromised.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
covid-19
-
News

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Rhea-AI Summary
Gilead Sciences presents positive clinical data on innovative HIV treatment research pipeline at CROI. The data includes studies on investigational combination regimens, long-acting dosing strategies, and once-weekly integrase strand transfer inhibitor. Results show potential for transforming HIV management and addressing unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
News

Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area

Rhea-AI Summary
Gilead Sciences, under the leadership of CEO Daniel O'Day, has seen significant growth and expansion in antiviral and cancer therapies. With a strong economic impact of $22.1 billion in 2020, the company boasts a diverse pipeline of new medicines across various diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Rhea-AI Summary
RedHill Biopharma's opaganib selected by U.S. government for evaluation as a medical countermeasure against Sulfur Mustard exposure. Opaganib, a novel oral small molecule, shows promise for multiple indications including COVID-19 and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News

Gilead Sciences: National Black HIV/AIDS Awareness Day

Rhea-AI Summary
National Black HIV/AIDS Awareness Day 2024 focuses on 'Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities'. C. Virginia Fields from National Black Leadership Commission on Health discusses Gilead's involvement as a grantee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
News

Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Rhea-AI Summary
Gilead Sciences, Inc. is providing $12.6 million in grant funding to 19 organizations through its Setting the P.A.C.E. Initiative to improve the HIV landscape for Black women and girls in the U.S. This initiative aims to increase HIV prevention efforts and health equity for Black cisgender and Transgender women and girls who are disproportionately affected by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

NYSE:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY